These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 9091654)
21. Prescription drug products; revocation of patient package insert requirements--Food and Drug Administration. Final rule. Fed Regist; 1982 Sep; 47(173):39147-55. PubMed ID: 10258154 [TBL] [Abstract][Full Text] [Related]
22. Proposed legislation--its impact on drug information processing. Cleveland CB; Adams J Drug Inf J; 1978; 12(3):181-4. PubMed ID: 10239117 [No Abstract] [Full Text] [Related]
23. [Patient education and specialty prescription information from the psychiatric viewpoint]. Linden M Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):662-7; discussion 667-8. PubMed ID: 9527465 [No Abstract] [Full Text] [Related]
24. Information on marketed drugs for doctors and patients. Experience in six European countries. Brown P; Charlish P; Brazier H; Butterfield M Int J Technol Assess Health Care; 1995; 11(3):410-6. PubMed ID: 7591543 [TBL] [Abstract][Full Text] [Related]
25. Communicating with patients about their medications. Kessler DA N Engl J Med; 1991 Dec; 325(23):1650-2. PubMed ID: 1944456 [No Abstract] [Full Text] [Related]
26. FDA's regulation of prescription drug labeling: a role for implied preemption. Kendrick LC Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031 [No Abstract] [Full Text] [Related]
27. Rx with a dose of info. Miller RW FDA Consum; 1980 Nov; 14(9):22-3. PubMed ID: 10309292 [TBL] [Abstract][Full Text] [Related]
28. A defense of the learned intermediary doctrine. Goetz RB; Growdon KR Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470 [No Abstract] [Full Text] [Related]
29. FDA proposes more stringent pediatric-use labeling of prescription drug products. Am J Hosp Pharm; 1993 Jan; 50(1):13, 16. PubMed ID: 8427271 [No Abstract] [Full Text] [Related]
30. Off-label or off-limits? Ratner M; Gura T Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236 [No Abstract] [Full Text] [Related]
31. Should expiration dates be required on patients' prescription labels? Hadeler F Am Pharm; 1986 Aug; NS26(8):30-5. PubMed ID: 3776829 [No Abstract] [Full Text] [Related]
32. Prescription drugs; revocation of final guideline patient package inserts and withdrawal of draft guideline patient package inserts--Food and Drug Administration. Notice. Fed Regist; 1982 Sep; 47(173):39249-50. PubMed ID: 10258155 [TBL] [Abstract][Full Text] [Related]
33. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate. Dorfman HL; Quinn VM; Brophy EA Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765 [No Abstract] [Full Text] [Related]
34. Introduction to the new prescription drug labeling by the Food and Drug Administration. Lal R; Kremzner M Am J Health Syst Pharm; 2007 Dec; 64(23):2488-94. PubMed ID: 18029957 [TBL] [Abstract][Full Text] [Related]
37. The case for preemption of prescription drug failure-to-warn claims. Kim CH Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969 [No Abstract] [Full Text] [Related]
39. Use of drugs for unlabeled indications. Nightingale SL Am Fam Physician; 1986 Sep; 34(3):269. PubMed ID: 3751849 [No Abstract] [Full Text] [Related]
40. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule. Food and Drug Administration, HHS Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]